BioNTech SE ADR (BNTX) News
Filter BNTX News Items
BNTX News Results
|Loading, please wait...|
BNTX News Highlights
- BNTX's 30 day story count now stands at 142.
- Over the past 27 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 23.
- AGE, SE and MRNA are the most mentioned tickers in articles about BNTX.
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023.
The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc''s (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc''s (NASDAQ: MRNA ) COVID-19 vaccines to reduce a rare risk of heart inflammation. The CDC said males ages 12- to 39-years-old should consider waiting eight weeks between the first and second doses of their primary COVID-19 vaccination series,
The European Union''s health regulator on Thursday (Feb 24) backed giving a booster shot of Pfizer and BioNTech''s COVID-19 vaccine to adolescents aged 12 and over, as well as the expanded use of Moderna''s shot in children ages six to 11. The recommendations by the European Medicine Agency''s (EMA) Committee
An advisory panel of the European Medicines Agency has recommended that Pfizer (PFE) and BioNTech''s (BNTX) COVID-19 vaccine be authorized as a booster to children 12 years and older.
Buying and holding quality growth stocks can be a surefire way to significantly increase your portfolio's value over the years. Two growth stocks that show lots of promise and are down more than 60% from their 52-week highs are BioNTech SE (NASDAQ: BNTX) and Matterport (NASDAQ: MTTR). Healthcare company BioNTech finished last week at less than $157 per share -- down more than 66% from the $464 it peaked at last Aug. 10, which was just after the release of its second-quarter results.
BioNTech (NASDAQ: BNTX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 1 0 1 0 0 According to 5 analyst offering 12-month price targets in the last 3 months, BioNTech has an average price target of $300.0 with a high of $366.00 and a low of $217.00. Below is a summary of how these 5 analysts rated BioNTech over the past 3 months. The greater the number of bullish ratings, the more positive … Full story available on Benzinga.com
H.C. Wainwright is maintaining its buy rating on BioNTech (BNTX), but is lowering its price target due to concerns on long-term sales of the company''s COVID-19 vaccine.
South Korea approved Pfizer (PFE) BioNTech''s (BNTX) coronavirus vaccine for use in children age five to 11 years, Reuters reported citing the Asian country''s food and drug ministry.The
Overview At the end of November 2021 I posted a note on Seeking Alpha discussing BioNTech (BNTX) and Moderna (MRNA), the 2 messenger-RNA giants whose vaccines - Moderna's SpikeVax, and BioNTech's Comirnaty - developed in partnership with Pfizer (PFE) - were the first two vaccines to be approved to treat...
BioNTech is acquiring a preclinical T cell receptor program (TCR) from Medigene, as well as licenses to the biotechs TCR technologies. The agreement helps BioNTech expand its scope in cancer immunotherapy with a new approach for addressing solid tumors.